KR102115203B1 - 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 - Google Patents

항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 Download PDF

Info

Publication number
KR102115203B1
KR102115203B1 KR1020197026462A KR20197026462A KR102115203B1 KR 102115203 B1 KR102115203 B1 KR 102115203B1 KR 1020197026462 A KR1020197026462 A KR 1020197026462A KR 20197026462 A KR20197026462 A KR 20197026462A KR 102115203 B1 KR102115203 B1 KR 102115203B1
Authority
KR
South Korea
Prior art keywords
ser
leu
val
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197026462A
Other languages
English (en)
Korean (ko)
Other versions
KR20190107749A (ko
Inventor
유타 아멜스도르페르
슈테판 슈테이들
마르크 빈테리히
수잔 크론
리사 로즈크예르
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20190107749A publication Critical patent/KR20190107749A/ko
Application granted granted Critical
Publication of KR102115203B1 publication Critical patent/KR102115203B1/ko
Assigned to 인사이트 코포레이션 reassignment 인사이트 코포레이션 권리의 전부이전등록 Assignors: 모르포시스 아게
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020197026462A 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 Active KR102115203B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
US61/523,861 2011-08-16
EP11177658.9 2011-08-16
EP11177658 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US61/647,539 2012-05-16
US201261654097P 2012-06-01 2012-06-01
US61/654,097 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147006936A Division KR20140064873A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014299A Division KR20200058583A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Publications (2)

Publication Number Publication Date
KR20190107749A KR20190107749A (ko) 2019-09-20
KR102115203B1 true KR102115203B1 (ko) 2020-05-28

Family

ID=47714801

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197026462A Active KR102115203B1 (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR1020147006936A Ceased KR20140064873A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR1020207014299A Withdrawn KR20200058583A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147006936A Ceased KR20140064873A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
KR1020207014299A Withdrawn KR20200058583A (ko) 2011-08-16 2012-08-14 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법

Country Status (24)

Country Link
US (3) US20140255427A1 (enExample)
EP (2) EP4062936A1 (enExample)
JP (1) JP6184952B2 (enExample)
KR (3) KR102115203B1 (enExample)
CN (1) CN103732252B (enExample)
AU (1) AU2012296907B2 (enExample)
BR (1) BR112013033919B1 (enExample)
CA (2) CA3137321A1 (enExample)
CY (1) CY1125122T1 (enExample)
DK (1) DK2744515T3 (enExample)
ES (1) ES2909722T3 (enExample)
HR (1) HRP20220228T1 (enExample)
HU (1) HUE058350T2 (enExample)
IL (1) IL230293B (enExample)
LT (1) LT2744515T (enExample)
MX (1) MX354479B (enExample)
PL (1) PL2744515T3 (enExample)
PT (1) PT2744515T (enExample)
RS (1) RS63238B1 (enExample)
RU (1) RU2625222C2 (enExample)
SG (1) SG10201606785UA (enExample)
SI (1) SI2744515T1 (enExample)
SM (1) SMT202200159T1 (enExample)
WO (1) WO2013024097A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157553A4 (en) * 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
JP6916741B2 (ja) 2015-05-26 2021-08-11 モルフォシス・アーゲー 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
HUE063119T2 (hu) 2017-05-31 2024-01-28 Morphosys Ag Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
US20230357392A1 (en) * 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2326389C (en) * 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
IL146005A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
BR112012003066A2 (pt) * 2009-08-14 2016-11-16 Roche Glycart Ag uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
WO2011057222A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Science Translational Medicine. Vol. 3, No. 95, 95ra73, pp. 1-11 (2011.08.10. 공개) 1부.*

Also Published As

Publication number Publication date
HRP20220228T1 (hr) 2022-05-13
DK2744515T3 (da) 2022-03-28
EP2744515B1 (en) 2022-02-09
HUE058350T2 (hu) 2022-07-28
SMT202200159T1 (it) 2022-05-12
LT2744515T (lt) 2022-04-25
SI2744515T1 (sl) 2022-05-31
BR112013033919B1 (pt) 2022-11-16
US20140255427A1 (en) 2014-09-11
ES2909722T3 (es) 2022-05-10
KR20190107749A (ko) 2019-09-20
KR20200058583A (ko) 2020-05-27
NZ617770A (en) 2016-01-29
CA2841875A1 (en) 2013-02-21
US20240366756A1 (en) 2024-11-07
RU2014103492A (ru) 2015-09-27
RS63238B1 (sr) 2022-06-30
CA3137321A1 (en) 2013-02-21
PT2744515T (pt) 2022-05-19
IL230293B (en) 2019-01-31
JP2014525926A (ja) 2014-10-02
US20200353077A1 (en) 2020-11-12
MX354479B (es) 2018-03-07
CY1125122T1 (el) 2024-12-13
AU2012296907B2 (en) 2017-01-05
CN103732252A (zh) 2014-04-16
RU2625222C2 (ru) 2017-07-12
BR112013033919A2 (pt) 2017-12-19
MX2013014933A (es) 2014-04-16
JP6184952B2 (ja) 2017-08-23
KR20140064873A (ko) 2014-05-28
EP2744515A1 (en) 2014-06-25
CA2841875C (en) 2021-11-02
EP4062936A1 (en) 2022-09-28
SG10201606785UA (en) 2016-10-28
PL2744515T3 (pl) 2022-05-30
WO2013024097A1 (en) 2013-02-21
CN103732252B (zh) 2017-11-10

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
US20240366756A1 (en) Combinations and uses thereof
KR102117202B1 (ko) 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
AU2022202800B2 (en) Combinations and uses thereof
JP2014525926A5 (enExample)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7